B
Black Diamond Therapeutics D
D
BDTX
2.18500
USD
0.04
(1.86%)
مفتوح الان
حجم التداول
26,026
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
125,536,437
العنوان: Black Diamond Therapeutics
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding ofcancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor,is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
